Verona Pharma Plc - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Verona Pharma Plc Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Verona Pharma Plc. The Group's principal activity is researching and developing drugs for the treatment of allergic rhinitis and other chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease as well as chronic inflammatory diseases. The Group's lead drug compound, RPL554, is a long acting inhibitor of both phosphodiesterase 3 and phosphodiesterase 4 enzymes, two enzymes known to be of importance in the development and progression of immunological respiratory diseases, particularly rhinitis (hay fever) and asthma.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report